Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients

We hope to see many of you at this event! Don't miss the next Ecosystem Breakfast on the topic: Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients With: Charles Marcaillou, Head of R&D, IntegraGen Charles is a senior scientist and molecular biologist with over 25 years of expertise in genomics and a pioneer in next-generation sequencing technologies. As head of R&D, he has overseen the development, validation, and optimization of the full range of NGS-based applications offered by the company. Séverine Matin-Lannerée, PhD, Head of Quality, IntegraGen Séverine oversees regulatory compliance and quality management for high-throughput sequencing services, with a focus on applications in clinical research and trials, including liquid biopsy. She joined IntegraGen in 2017 after a career in academic and translational research on the molecular bases and mechanisms of cancer. She initially led R&D projects within the oncology biomarker team and acted as a scientific advisor. Céline Capéra, Head of Sales, IntegraGen Céline has led IntegraGen's Commercial team since 2021. Having joined the team in 2010, she has helped IntegraGen become a European leader in genomics services and precision medicine. She has a strong background in NGS and genomics technologies